Botulinum Toxin-A Dosing Trends for Adductor Spasmodic Dysphonia at a Single Institution Over 10 Years

Joseph P. Bradley; Emily M. Barrow; Edie R. Hapner; Adam M. Klein; Michael M. Johns

doi:10.1016/j.jvoice.2016.09.022

Botulinum Toxin-A Dosing Trends for Adductor Spasmodic Dysphonia at a Single Institution Over 10 Years

Joseph P. Bradley, Emily M. Barrow, Edie R. Hapner, Adam M. Klein, Michael M. Johns

Department of Otolaryngology

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Objectives This study aimed to identify the changes in dosing of botulinum toxin-A for adductor spasmodic dysphonia (ADSD) over a prolonged period. Study Design This is a retrospective chart review. Methods One hundred thirteen subjects treated for ADSD from 2003 to 2013 were identified from a clinical database. Subject age, gender, and total injection dose amount were all recorded for all subjects who had at least 10 injections. Results Fifty-four subjects met criteria for inclusion. There were no age or gender differences in the starting dose for subjects. Dosing decreased significantly compared with the second dose (5.05 ± 1.623 Units), by the sixth dose (4.26 ± 1.698 Units), and continued through the 10th dose (4.08 ± 2.019 Units) (P < 0.005 for all). Conclusions Botulinum toxin-A dosing for ADSD decreases consistently over subsequent injections after the initial two dose titrations.

Original language	English
Pages (from-to)	363-365
Number of pages	3
Journal	Journal of Voice
Volume	31
Issue number	3
DOIs	https://doi.org/10.1016/j.jvoice.2016.09.022
State	Published - May 2017

Keywords

Adductor spasmodic dysphonia
Botox
Botulinum toxin-A
Dosing
Laryngeal dystonia

Access to Document

10.1016/j.jvoice.2016.09.022

Cite this

@article{03bb103f937944c48c76b38349698948,

title = "Botulinum Toxin-A Dosing Trends for Adductor Spasmodic Dysphonia at a Single Institution Over 10 Years",

abstract = "Objectives This study aimed to identify the changes in dosing of botulinum toxin-A for adductor spasmodic dysphonia (ADSD) over a prolonged period. Study Design This is a retrospective chart review. Methods One hundred thirteen subjects treated for ADSD from 2003 to 2013 were identified from a clinical database. Subject age, gender, and total injection dose amount were all recorded for all subjects who had at least 10 injections. Results Fifty-four subjects met criteria for inclusion. There were no age or gender differences in the starting dose for subjects. Dosing decreased significantly compared with the second dose (5.05 ± 1.623 Units), by the sixth dose (4.26 ± 1.698 Units), and continued through the 10th dose (4.08 ± 2.019 Units) (P < 0.005 for all). Conclusions Botulinum toxin-A dosing for ADSD decreases consistently over subsequent injections after the initial two dose titrations.",

keywords = "Adductor spasmodic dysphonia, Botox, Botulinum toxin-A, Dosing, Laryngeal dystonia",

author = "Bradley, {Joseph P.} and Barrow, {Emily M.} and Hapner, {Edie R.} and Klein, {Adam M.} and Johns, {Michael M.}",

year = "2017",

month = may,

doi = "10.1016/j.jvoice.2016.09.022",

language = "English",

volume = "31",

pages = "363--365",

journal = "Journal of Voice",

issn = "0892-1997",

number = "3",

}

TY - JOUR

T1 - Botulinum Toxin-A Dosing Trends for Adductor Spasmodic Dysphonia at a Single Institution Over 10 Years

AU - Bradley, Joseph P.

AU - Barrow, Emily M.

AU - Hapner, Edie R.

AU - Klein, Adam M.

AU - Johns, Michael M.

PY - 2017/5

Y1 - 2017/5

N2 - Objectives This study aimed to identify the changes in dosing of botulinum toxin-A for adductor spasmodic dysphonia (ADSD) over a prolonged period. Study Design This is a retrospective chart review. Methods One hundred thirteen subjects treated for ADSD from 2003 to 2013 were identified from a clinical database. Subject age, gender, and total injection dose amount were all recorded for all subjects who had at least 10 injections. Results Fifty-four subjects met criteria for inclusion. There were no age or gender differences in the starting dose for subjects. Dosing decreased significantly compared with the second dose (5.05 ± 1.623 Units), by the sixth dose (4.26 ± 1.698 Units), and continued through the 10th dose (4.08 ± 2.019 Units) (P < 0.005 for all). Conclusions Botulinum toxin-A dosing for ADSD decreases consistently over subsequent injections after the initial two dose titrations.

AB - Objectives This study aimed to identify the changes in dosing of botulinum toxin-A for adductor spasmodic dysphonia (ADSD) over a prolonged period. Study Design This is a retrospective chart review. Methods One hundred thirteen subjects treated for ADSD from 2003 to 2013 were identified from a clinical database. Subject age, gender, and total injection dose amount were all recorded for all subjects who had at least 10 injections. Results Fifty-four subjects met criteria for inclusion. There were no age or gender differences in the starting dose for subjects. Dosing decreased significantly compared with the second dose (5.05 ± 1.623 Units), by the sixth dose (4.26 ± 1.698 Units), and continued through the 10th dose (4.08 ± 2.019 Units) (P < 0.005 for all). Conclusions Botulinum toxin-A dosing for ADSD decreases consistently over subsequent injections after the initial two dose titrations.

KW - Adductor spasmodic dysphonia

KW - Botox

KW - Botulinum toxin-A

KW - Dosing

KW - Laryngeal dystonia

UR - http://www.scopus.com/inward/record.url?scp=85006257909&partnerID=8YFLogxK

U2 - 10.1016/j.jvoice.2016.09.022

DO - 10.1016/j.jvoice.2016.09.022

M3 - Article

C2 - 27839987

AN - SCOPUS:85006257909

SN - 0892-1997

VL - 31

SP - 363

EP - 365

JO - Journal of Voice

JF - Journal of Voice

IS - 3

ER -

Botulinum Toxin-A Dosing Trends for Adductor Spasmodic Dysphonia at a Single Institution Over 10 Years

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this